No description available.

No description available.

Master of Science / Department of Chemistry / Ping Li / Biodegradable polyhydroxybutyrates (PHBs) produced by a wide range of bacteria have been considered as an ideal alternative to petroleum-based plastics. Two types of mechanistic probes have been synthesized in order to understand the mechanism of PHB synthases (PhaCs). The first type is oxo analogs in which the sulfur in the coenzyme A (CoA) thioester has been replaced with an oxygen atom. A series of 3-R-hydroxybutyryl oxo CoA analogs, (HB)[subscript]nOCoA (n = 1, 2 and 3), were synthesized chemoenzymatically in good yields. Two models involving covalent catalysis with Cys have been proposed for the chain elongation catalyzed by PhaCs. The first involves an active site composed of two monomers in which the growing hydroxybutyrate (HB) chain alternates between Cys on each monomer. The second involves noncovalent intermediates (HB)[subscript]nCoA (n ≥ 2). Here the substrate analog HBOCoA was successfully employed to trap the noncovalent intermediates in the reactions catalyzed by class III PhaC from Allochromatium Vinosum, which supports our preferred second mechanistic model. Furthermore, it is also the first time that a wild-type (wt) synthase was used to investigate the chain elongation models. The other type of mechanistic probes is 3-R-hydroxyalkyl CoA that was used to investigate the substrate specificity of PhaCs from different classes. Substrate availability has been a challenge to study PHB synthases in vitro. Starting with commercially available dimethyl S-malate, the intermediate S-ethyl 2-(oxiran-2-yl) acetate 23 was synthesized via a ring-opening reaction involving lactone 21 and trimethylsilyl iodide followed by an oxidation reaction involving silver oxide. The regiospecific ring-opening reaction of epoxide 23 with different organometallic reagents afforded a straightforward access to ethyl 3-R-hydroxybutanoates attached with a variety of side chains. The final CoA compounds were obtained through the thiotransesterification reaction between corresponding benzenethioesters and the thiol group in CoA. This synthetic approach provides a new avenue to modifications of alkyl groups in 3-R-hydroxyalkyl CoA in an efficient manner.

<p>Acetyl-CoA holds a prominent position as the common metabolic intermediate of glucose, amino acid and fatty acid oxidation. Because acetyl-CoA fuels the tricarboxylic acid (TCA) cycle, the primary source of reducing equivalents that drives mitochondrial oxidative phosphorylation, understanding acetyl-CoA pool regulation becomes imperative to understanding mitochondrial energetics. Carnitine acetyltransferase (CrAT), a muscle-enriched mitochondrial enzyme, catalyzes the freely reversible conversion of acetyl-CoA to its membrane permeant carnitine ester, acetylcarnitine. Because CrAT has long been thought to regulate the acetyl-CoA metabolite pool, we investigated the role of CrAT in acetyl-CoA regulation. Although the biochemistry and enzymology of the CrAT reaction has been well studied, its physiological role remains unknown. Investigations herein suggest that CrAT-mediated maintenance of the mitochondrial acetyl-CoA pool is imperative for preservation of energy homeostasis. We provide compelling evidence that CrAT is critical for fine-tuning acetyl-CoA balance during the fasted to fed transition and during exercise. These studies suggest that compromised CrAT activity results in derangements in mitochondrial homeostasis.</p><p>In chapter 3, we examined the effects of obesity and lipid exposure on CrAT activity. Recent studies have shown that acetyl-CoA-mediated inhibition of pyruvate dehydrogenase (PDH), the committed step in glucose oxidation, is modulated by the CrAT enzyme. Because PDH and glucose oxidation are negatively regulated by high fat feeding and obesity, we reasoned that nutritional conditions that promote lipid availability and fat oxidation might likewise compromise CrAT activity. We report an accumulation of long chain acylcarnitines and acyl-CoAs but a decline in the acetylcarnitine/acetyl-CoA ratio in obese and diabetic rodents. This reduction in the skeletal muscle acetylcarnitine/acetyl-CoA ratio was accompanied by a decrease in CrAT specific activity, despite increased protein abundance. Exposure to long chain acyl-CoAs in vitro demonstrated that palmitoyl-CoA acts as a mixed model inhibitor of CrAT. Furthermore, primary human skeletal muscle myocytes exposed to fatty acid and or CPT1b overexpression had elevated long chain acylcarnitines but decreased production and efflux of CrAT-derived short chain acylcarnitines. These data suggest that exposure to fatty acids in obesity and diabetes can counter-regulate the CrAT enzyme leading to decreased activity. </p><p>Alternatively, chapter 4 addresses the importance of acetyl-CoA buffering during exercise and suggests that a deficit in CrAT activity leads to fatigue. Because CrAT is highly expressed in tissues specifically designed for work and because acetylcarnitine, the primary product of the CrAT reaction, is increased during contraction, we reasoned that CrAT could play an important role in exercise. To investigate this possibility, we employed exercise intervention and ex-vivo analysis on a genetically novel mouse model of skeletal muscle CrAT deficiency (CrATSM-/-). Though resting acetyl-CoA levels were elevated in CrATSM-/- mice, these levels dropped significantly after intense exercise while acetylcarnitine content followed the opposite pattern. This contraction-induced acetyl-CoA deficit in CrATSM-/- mice was coupled with compromised performance and diminished whole body glucose oxidation during high intensity exercise. These results imply that working muscles clear and consume acetylcarnitine in order to maintain acetyl-CoA buffering during exercise. Importantly, provision of acetylcarnitine enhanced force generation, delayed fatigue and improved mitochondrial energetics in muscles from CrATfl/fl controls but not CrATSM-/- littermates, emphasizing the importance of acetyl-CoA maintenance. In aggregate, these data demonstrate a critical role for CrAT-mediated acetyl-CoA buffering in exercise tolerance and suggest its involvement in energy metabolism during skeletal muscle contraction and fatigue. These findings could have important clinical implications for individuals with muscle weakness and fatigue due to multiple conditions, such as peripheral vascular or cardiometabolic disease. </p><p>In summary, data herein emphasize the role of CrAT in regulation of mitochondrial acetyl-CoA pool. We demonstrate that CrAT is critical for fine-tuning acetyl-CoA balance both during the fasted to fed transition and during exercise. These data suggest that a deficit in CrAT activity leads to glucose intolerance and exercise fatigue. We examine these studies and suggest future areas of study.</p> / Dissertation

With crude oil demand rising and supplies being depleted, alternative energy, specifically biofuels, are of intense scientific interest. Current plant crop based biofuels suffer from several problems, most importantly the use of land needed for food. Cyanobacteria offer a solution to this problem as they do not compete with land for food and produce hydrocarbons that can be used as biofuels. Upon examination of metabolic pathways competing with hydrocarbon synthesis, it appeared that cyanobacteria lacked the major fatty acid degradative metabolic pathway β-oxidation, generally thought to be a universally occurring pathway. Lack of this pathway in cyanobacteria was confirmed by employing a range of analytical techniques. Bioinformatic analysis suggested that potential enzymes with β-oxidation activity were involved in other metabolic pathways. A sensitive assay was set up to detect acyl- CoAs, the substrates of β-oxidation, using liquid chromatography triple quadrupole mass spectrometry. None could be detected in cyanobacteria. No enzymatic activity from the rate-limiting acyl-CoA dehydrogenase/oxidase could be detected in cyanobacterial extracts. It was found that radiolabeled fatty acids fed to cyanobacteria were utilised for lipid membranes as opposed to being converted to CO2 by respiration or into other compounds by the TCA cycle. An element of the β-oxidation pathway, E. coli acyl-CoA synthetase was ectopically expressed in a strain of cyanobacteria and implications of the introduction of acyl-CoA synthesis were assessed. Finally, the regulation of the fatty acid biosynthetic pathway was investigated. It was determined that under conditions of excess fatty acid, the transcription of acetyl-CoA carboxylase and enoyl-ACP reductase was repressed and acyl-ACP synthetase involved in fatty acid recycling was induced. These results were discussed in relation to fatty acid oxidation and hydrocarbon biosynthesis in other organisms.

Im Katabolismus methylverzweigter Fettsäuren spielt die alpha-Methylacyl-CoA-Racemase eine wichtige Rolle, indem sie die (R)- und (S)-Isomere von alpha-methylverzweigten Fettsäuren als Coenzym A Thioester racemisiert. Methylverzweigte Fettsäuren entstehen beim Abbau von Isoprenoiden und werden darüber hinaus auch von vielen Organismen, wie z.B. Mycobakterien, synthetisiert. Die Hauptaufgabe der Racemase ist aber vermutlich in der Biosynthese von Gallensäuren zu sehen. Das Ziel der vorliegenden Arbeit war es, die alpha-Methylacyl-CoA-Racemase aus humanem Gewebe zu reinigen und zu charakterisieren sowie ihre physiologische Rolle im Katabolismus verzweigtkettiger Fettsäuren und der Gallensäurebiosynthese zu untersuchen. Die alpha-Methylacyl-CoA-Racemase wurde aus humanem Gewebe zur Homogenität gereinigt, umfassend biochemisch charakterisiert und zur genauen molekularbiologischen Analyse in E.coli kloniert. Die Aktivität der Racemase wurde anhand der [³H]H2O-Freisetzung aus [alpha-³H]-a-Methylacyl-CoAs bestimmt. Die humane Racemase ist in der aktiven Form ein monomeres Protein und besteht aus 382 Aminosäuren. Als Substrate akzeptiert das Enzym ein breites Spektrum von alpha-Methylacyl-CoAs. Neben den Coenzym A-Thioestern alpha-methylverzweigter Fettsäuren, wie Pristansäure, werden auch CoA-Ester von Steroidderivaten, z.B. des Gallensäureintermediats Trihydroxycoprostansäure, und aromatischen Phenylpropionsäuren, wie dem Analgetikum Ibuprofen, umgesetzt. Freie Fettsäuren, geradkettige oder beta-methylverzweigte Acyl-CoAs werden nicht racemisiert. Die alpha-Methylacyl-CoA-Racemase ist im Menschen zu ca. 80 Prozent auf die Peroxisomen und ca. 20 Prozent auf die Mitochondrien verteilt, wobei entsprechende peroxisomale (PTS 1) und mitochondriale (MTS) Transportsignale die Lokalisation bestimmen. Die vollständige cDNA-Sequenz der humanen a-Methylacyl-CoA-Racemase hat eine Gesamtlänge von 2039 Basenpaaren mit einem offenen Leseraster von 89 - 1237 bp. Das Startcodon ATG ist in eine klassische Kozak-Sequenz zum Translationsstart eingebettet. Die Protein endet am C-Terminus mit dem Sequenzmotiv –KASL, das dem peroxisomalen Transportsignal (PTS I) einiger Säugetierkatalasen entspricht. Aufgrund alternativer Polyadenylierung sind in allen untersuchten menschlichen Geweben Transkripte von 1,6 kb bzw. 2,0 kb zu finden. Es liegt keine gewebsabhängige Polyadenylierung vor, die Racemase wird aber gewebsspezifisch exprimiert (besonders stark in Leber und Niere). Das humane Racemasegen liegt auf dem kurzen Arm des Chromosoms 5 nahe am Centromer (5p1.3), im Intervall von D5S651 (46,6 cM) und D5S634 (59.9 cM). / Racemization is an essential step for bile acid synthesis and it is important for degradation of alpha-methyl branched-chain fatty acids. The (R)- and (S)-isomers of alpha-methyl-branched chain fatty acids were shown to be interconverted as coenzyme A thioesters by an alpha-methylacyl-CoA racemase. Various branched-chain fatty acids arise in the catabolism of isoprenoids and are also synthesized by a variety of organisms, particularly mycobacteria. The aim of this work was to purify and to characterize the racemase from human tissue and to analyse the physiological role in the degradation of branched-chain fatty acids and the bile acid synthesis. The alpha-methylacyl-CoA racemase was purified from human liver to apparent homogeneity. The enzyme was exhaustively characterized by methods of biochemistry and protein chemistry. The cDNA coding for human racemase was cloned in E. coli and sequenced. A radiometric assay with 2-methyl[2-³H]acyl-CoAs as substrates was used routinely for monitoring purification procedure. The active form of the enzyme is a monomeric protein comprising 382 amino acids. The enzyme accepts a wide range of alpha-methylacyl-CoAs, including pristanoyl-CoA, trihydroxycoprostanoyl-CoA (an intermediate in bile acid synthesis) as substrates. Also arylpropionyl-CoAs such as the anti-inflammatory drug ibuprofen are accepted, but neither free fatty acids, beta-methyl-branched nor linear-chain acyl-CoAs. In human tissues 80 - 90 Prozent of the racemase activity is found in peroxisomes and 10 - 20 Prozent in mitochondria. Degradation of branched chain fatty acids is located in both compartments, so the enzyme has to be distributed between peroxisomes and mitochondria. No evidence was found for the existence of isoenzymes or different transcription products. It appears that only one mRNA is transcribed from one gene and that also only one protein is synthesized. The different recognition of peroxisomal (PTS 1) and mitochondrial targeting signals (MTS) may determine the subcellular distribution. The complete cDNA sequence has an overall length of 2039 base pairs, with a open reading frame between 89 - 1237 bp. The ATG start codon is embedded in a classical Kozak sequence for translation start. The C-Terminus of the protein is –KASL, which is very similar to the peroxisomal targeting signals (PTS 1) of many mammalian catalases. In all human tissues analysed in this work two different transcripts of racemase with sizes of 1,6 kb and 2,0 kb have been found and show alternate polyadenylation. Polyadenylation of racemase is not tissue-dependent but its expression is tissue-specific (strong activity is found in liver and kidney). The human racemase gene is localized on the short arm of chromosome 5, near the centromer (region 5p1.3) and between the markers D5S651 (46,6 cM) and D5S634 (59.9 cM).

Zahlreiche strikt anaerob lebende Mikroorganismen, darunter acetogene Bakterien, Sulfatreduzierer und methanogene Archaeen, nutzen den reduktiven Acetyl-CoA-Weg zur autotrophen Kohlenstoff-Fixierung oder Energiegewinnung. Die letzten Schritte der Acetyl-CoA-Bildung beruhen hierbei auf dem Zusammenspiel dreier Proteine, dem Corrinoid-Eisen/Schwefel-Protein (CoFeSP), der Methyltetrahydrofolat:CoFeSP-Methyltransferase (MeTr) und dem Acetyl-CoA-Synthase/CO-Dehydrogenase-Komplex (ACS/CODH). In der vorliegenden Arbeit wurde die Substratbindung an MeTr durch thermodynamische und kinetische Messungen untersucht. MeTHF bindet stärker an das Enzym als das demethylierte Produkt Tetrahydrofolat (THF) und scheint dabei einem einstufigen Bindungsmodell zu folgen. Das Substrat wird bei der Bindung an MeTr protoniert, wobei Asn200 eine protonierte H-N5(+)-CH3-Position des MeTHF durch eine alternative Konformation stabilisieren könnte. Asp44 und Asp76 bilden eine funktionelle Dyade bei der Substratbindung, kommen als Protondonoren zur Substrataktivierung jedoch nicht in Frage. Die Kristallstruktur von CoFeSP wurde erstmals vollständig mit der flexiblen N-terminalen [4Fe4S]-Cluster-Bindedomäne bestimmt. Die für die Cobalamin-Bindedomäne erwarteten Konformationsänderungen wurden anhand der Interaktion mit dem reduktiven Aktivator von CoFeSP (RACo) analysiert. Durch Förster-Resonanzenergietransfer wurde eine Annäherung der ortsspezifisch markierten CoFeSP-Positionen beobachtet und anhand des Fluoreszenzsignals die Kinetik der Komplexbildung mit RACo bestimmt. Durch gepulste Elektronendoppelresonanz konnte ebenfalls eine Abstandsänderung nachgewiesen werden. ACS wurde als apo-Enzym gereinigt und durch NiCl2-Rekonstitution in die aktive Form überführt. Durch die Kristallisation der C-terminalen ACS-Domäne wurden hochaufgelöste Strukturen erzeugt, welche eine Diskussion der strukturellen Details des aktiven Zentrums ermöglichen. / Several anaerobic microorganisms, including acetogenic bacteria, sulfate-reducing bacteria and methanogenic archaea operate the reductive acetyl-CoA pathway for autotrophic carbon fixation or to gain energy. The last steps of acetyl-CoA formation rely on three enzymes, the corrinoid-iron/sulfur-protein (CoFeSP), the methyltetrahydrofolate:CoFeSP methyltransferase (MeTr) and the acetyl-CoA synthase/CO dehydrogenase complex (ACS/CODH). Substrate binding to MeTr was investigated by thermodynamic and kinetic meassurements. MeTHF binds slightly stronger than the demethylated product tetrahydrofolate (THF), likely following a simple one-step-binding mechanism. Substrate binding to MeTr is coupled to proton uptake. A H-N5(+)-CH3-transition state of MeTHF could be stabilized by an alternative conformation of Asn200. Asp44 and Asp76 form a functional dyade in substrate binding but can be excluded as proton donors for substrate activation. The crystal structure of CoFeSP was solved completely, including the previously disordered N-terminal [4Fe4S]-cluster binding domain. The expected conformational change of the corrinoid binding domain was characterized by analyzing the interaction between CoFeSP and its reductive activator (RACo). An approach of the labeled CoFeSP positions in the CoFeSP:RACo complex was observed by Förster resonance energy transfer. Based on the corresponding fluorescence signal, the kinetics of complex formation were meassured in solution. Pulsed electron double resonance also showed that the labeled positions approach upon complex formation. Full-length ACS was purified in the apo state. A reconstitution of the A-cluster with NiCl2 resulted in active enzyme. Different crystal structures of the isolated C-terminal domain of ACS were solved at high resolution. Therefore, structural details of the active site could be discussed.

Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) is the most common inborn error of metabolism affecting the fatty acid oxidation pathway. The deficiency is caused by a defect in the medium-chain acyl-CoA dehydrogenase enzyme which catalyzes the first step in the oxidation of medium-chain fatty acids. Long-chain fatty acids, after being transported into the mitochondria and activated into long-chain acyl-CoAs, are sequentially broken down until they become medium-chain acyl-CoAs. Medium-chain acyl-CoAs are then broken down until they become short-chain acyl-CoAs. Short-chain acyl-CoAs are broken down until only acetyl-CoA remains. The block in the oxidation of fatty acids in those with MCADD happens once the long-chain acyl-CoAs have been oxidized to medium-chain acyl-CoAs. The medium-chain acyl-CoAs cannot be further oxidized and build up. Without the breakdown of fatty acids, individuals with MCADD cannot produce enough energy during times of increased metabolic demand. Thus, prolonged exercise, fasting, or fever can precipitate clinical symptoms once the body enters a hypoketotic hypoglycemic state. Those with MCADD typically present in the early months of life with fasting intolerance, vomiting, lethargy, and, in more serious cases, seizures. Adult presentation is rare, but should not be ruled out of a differential diagnosis, because early detection and intervention can prevent permanent brain damage and death. Because early detection can prevent the serious effects of metabolic decompensation, MCADD was added to the Newborn Screen and is tested through measuring levels of medium-chain acylcarnitines in dried blood smears by tandem mass spectrometry. Metabolic decompensation is manifested clinically through dehydration, vomiting, and acidosis. In serious cases, metabolic decompensation can progress to seizures, coma, and death. Introduction of the Newborn Screen has reduced the morbidity of the deficiency, but has not eliminated it. Those with MCADD need to be closely monitored and emergency glucose needs to be available to them in case of a hypoglycemic emergency. The Newborn Screen has been effective in finding mutations in the ACADM gene that produce a mild phenotype of MCADD. Before the Newborn Screen, the most common variant, K329E, was detected in clinically diagnosed patients. However, the screen has shown that there are about 150 variants leading to MCADD. The most common variant of the MCAD protein, K329E, has been studied and characterized in order to further understand the pathogenesis of MCADD. This mutation substitutes a lysine for a glutamic acid, introducing hindrance and the inability of the protein to form its fully functional tetrameric form. The mutant protein also has an increased sensitivity to heat denaturation. Currently, there are no pharmacological treatments for MCADD. The idea of pharmacological chaperones is explored by using the example of tetrahydrobiopterin and phenylketonuria. Future studies will need be done to find a treatment for MCADD that is curative rather than treating the symptoms of the deficiency; however, curative therapies which target the mutant enzyme may be problematic since there is a wide array of mutations that result in a defective enzyme in affected individuals.

As revisões sistemáticas são consideradas os desenhos experimentais capazes de guiar os cuidados em saúde. Contudo, as revisões narrativas ainda são largamente publicadas até o presente momento. No âmbito do tratamento das doenças periodontais, diversos estudos têm reportado que o uso adjuvante de estatinas à terapia periodontal mecânica pode acarretar melhorias nos parâmetros clínicos periodontais, como adicionais reduções de profundidade de sondagem e ganhos de inserção clínica. O objetivo deste trabalho é contextualizar a informação advinda de uma revisão sistemática realizada sobre um tema clínico significativo e compreender qual o seu papel como suporte da atenção ao paciente periodontal, a partir da compreensão obtida no estudo bibliométrico de revisões de literatura. No estudo bibliométrico, uma amostra representativa das revisões de literatura, publicadas na base Scopus, foi selecionada. Tipo de revisão, número de citações, ano de publicação, temática do estudo e outras variáveis foram coletadas. Nesse estudo, observou-se que o número de revisões sistemática tem aumentado significativamente ao longo dos anos quando comparados com o número de revisões narrativas. Apesar disso, o número ajustado de citações das revisões sistemáticas não difere significativamente das recebidas nas revisões narrativas. Já na revisão sistemática de uso adjuvante de estatinas, uma estratégia de busca nas bases Pubmed, Scopus e Embase foi realizada para identificar todos os ensaios clínicos que tenham utilizado estatinas como adjuvantes ao tratamento periodontal mecânico em comparação à terapia periodontal mecânica isolada ou associada a placebo. Quinze estudos foram selecionados. Observou-se que, na maioria dos estudos, o uso adjuvante de estatina apresentou adicionais reduções de profundidade de sondagem e ganhos de inserção clínica quando comparado com seus respectivos grupos controles. Contudo, a alta heterogeneidade desse resultado e o grande número de estudos ser executado por um mesmo grupo de pesquisa são fatores limitadores dessa revisão sistemática. Dessa maneira, pode-se concluir que o número de revisões sistemáticas vem aumentando a longo do tempo, porém o seu número de citações parece não acompanhar as mesmas tendências. Além disso, o uso adjuvante de estatina na terapia periodontal ainda não deve ser recomendado até a execução de outros estudos com melhor qualidade. / Systematic review is considered the experimental design capable of guiding the health care. However, narrative reviews are broadly published nowadays. Regarding periodontal diseases treatment, several studies reported that the adjuvant use of statins to mechanical periodontal treatment may promote additional improvements in clinical periodontal parameters, such as additional reduction in probing depth and clinical attachment gain. This study aimed to contextualize the information obtained in a systematic review about a significant clinical thematic and comprehend is its role in the periodontal care, through information gathered in a bibliometric study of literature review studies in Dentistry. In the bibliometric study, a representative sample of literature reviews studies, published in Scopus database, was selected. Type of review, number of citations, year of publication, study thematic, and other variables were collected. It was showed that the number of systematic reviews increased throughout the years in comparison to narrative reviews. Additionally, the Dentistry clinical fields presented the highest number of published systematic reviews. Despite of that, the mean adjusted number of citations granted for systematic reviews did not differ from the narrative ones. Regarding the performed systematic review, a search strategy was conducted on Pubmed, Scopus, and Embase databases to identify all clinical trials that used statins as adjuvant to mechanical periodontal treatment in comparison to mechanical periodontal treatment alone or in association with placebo. Fifteen studies were included. It was showed that most of the included studies presented additional reduction in probing depth and clinical attachment gain in comparison to their control groups. However, the high heterogeneity among the studies and the high number of studies conducted by the same research group are limitations of the present systematic review. It was concluded that the number of systematic review are increasing dramatically throughout the years, but this trend is not followed by the number of citations granted to this type of study. Furthermore, the adjuvant use of statin in the mechanical periodontal therapy may not be recommended until further well-designed studies have been published.

nÃo hà / O aumento nos Ãltimos anos de indivÃduos imunocomprometidos, como portadores da SÃndrome da ImunodeficiÃncia Adquirida, de doenÃas malignas, transplantados e outros usuÃrios de terapias imunossupressoras, favorece o surgimento de infecÃÃes oportunistas, principalmente as de teor fÃngico, como a candidÃase e a criptococose. Apesar de a terapia antifÃngica atual ser eficiente na maioria dos casos, algumas vezes fazem-se necessÃrias novas drogas que atuem como alternativa ou como coadjuvantes no tratamento para potencializar o efeito dos antifÃngicos utilizados. As estatinas sÃo fÃrmacos hipolipemiantes mais prescritos mundialmente para doenÃas cardiovasculares. Entretanto, recentemente, tem sido descritos outros efeitos benÃficos destas drogas, como, por exemplo, o controle de infecÃÃes. Este trabalho teve como objetivo determinar a atividade antifÃngica in vitro das estatinas ante 51 cepas de Candida, sendo 16 de C. albicans, 11 de C. krusei, 12 de C. tropicalis e 12 de C. parapsilosis, e 25 cepas de Cryptococcus, sendo 12 de C. gattii e 13 de C. neoformans, por meio de testes de microdiluiÃÃo em caldo, segundo documento M27-A3 padronizado pelo CLSI. O intervalo de concentraÃÃo testado para pravastatina foi de 50 a 0,0977 mg/mL, para sinvastatina, 1 a 0,0020 mg/mL e para atorvastatina, 10 a 0,0200 mg/mL. Pravastatina inibiu 37 leveduras do gÃnero Candida apresentando concentraÃÃo inibitÃria mÃnima (CIM) na faixa de 1,56 a 6,25 mg /mL e as cepas restantes nÃo foram inibidas mesmo na maior concentraÃÃo testada (50 mg /mL), enquanto que sinvastatina e atorvastatina apresentaram atividade antifÃngica sobre todas as 51 cepas avaliadas, apresentando CIMs de 0,02 a 1 mg / mL e 0,04 a 5,00 mg / mL, respectivamente. Para o gÃnero Cryptococcus, apenas 4 cepas foram inibidas ante a pravastatina (CIM = 25 mg / mL), por outro lado, sinvastatina inibiu todas as 25 cepas (CIM = 0,06 a 1 mg / mL), e atorvastatina apenas 8 cepas (CIM = 0,62 a 2,5 mg / mL), sendo que as 17 restantes nÃo foram inibidas mesmo na maior concentraÃÃo testada ( &#8805; 10 mg / mL). Foi determinada concentraÃÃo fungicida mÃnima (CFM) de pravastatina sobre 15 cepas do gÃnero Candida (CFM = 3,12 a 25 mg / mL), de sinvastatina sobre 34 cepas (CFM = 0,03 a 1 mg / mL), e de atorvastatina sobre 16 cepas (CFM = 0,04 a 0,31 mg / mL). Para o gÃnero Cryptococcus, das 25 cepas testadas, pravastatina exibiu CFM sobre apenas 3 cepas (CFM = 50 mg / mL), sinvastatina sobre 21 cepas (CFM = 0,12 a 1 mg / mL), e atorvastatina sobre 1 cepa (CFM = 1 mg / mL). Esta atividade inibitÃria in vitro de estatinas sobre espÃcies de Candida e Cryptococcus, abre uma perspectiva importante para a investigaÃÃo do possÃvel uso destas drogas com finalidade antifÃngica in vivo. / In the past years, fungal opportunistic infections, especially, candidiasis and cryptococcosis, have become more frequent because of the increase in the number of immunocompromised individuals, such as AIDS, transplant and cancer patients and those that are on immunosuppressive therapy. In spite of being effective, sometimes it is necessary to use new drugs as alternatives or as adjuvants in order to potentiate the effect of the classical antifungal therapy. Statins are the most prescribed hypolipemiant drugs worldwide for preventing cardiovascular diseases. However, other benefic effects for these drugs have been described, such as the control of infections. This work aimed at determining the antifungal activity of statins against Candida spp. and Cryptococcus spp. The minimum inhibitory concentrations (MICs) for three different statins (pravastatin, simvastatin and atorvastatin) were determined against 51 strains of Candida spp. (16 C. albicans, 11 C.krusei, 12 C. tropicalis and 12 C. parapsilosis) and 25 strains of Cryptococcus spp. (12 C. gattii and 13 C. neoformans), through broth microdilution assay, according to the Clinical Laboratory Standards Institute (CLSI - Document M27-A3). The concentration tested for pravastatin ranged from 50 to 0.0977 mg/mL, for simvastatin, it ranged from 1 to 0.0020 mg/mL and, for atorvastatin, it varied from 10 to 0.0200 mg/mL. Pravastatin inhibited 37 Candida strains, with MICs varying from 1.56 to 6.25 mg/mL and the remaining strains were not inhibited, even at the highest concentration tested (50 mg/mL). Simvastatin and atorvastatin, on the other hand, inhibited all 51 Candida strains evaluated, presenting MICs ranging from 0.02 to 1 mg/mL and from 0.04 to 5 mg/mL, respectively. Concerning Cryptococcus spp., only four strains were inhibited by pravastatin (MIC=25 mg/mL), while all 25 strains were inhibited by simvastatin (0.06&#8804;MIC&#8804;1 mg/mL) and eight were inhibited by atorvastatin (0.62&#8804;MIC&#8804;2.5 mg/mL) and the remaining 17 were not susceptible to the highest atorvastatin concentration tested (10 mg/mL). The minimum fungicidal concentrations (MFCs) for the tested statins were also determined. The MFC for pravastatin against Candida spp. was determined against 15 strains (3.12&#8804;MIC&#8804;25 mg/mL). The MFC values for simvastatin were determined for 34 strains of Candida spp. (0.03&#8804;MFC&#8804;1 mg/mL), while those for atorvastatin were determined against 16 strains (0.04&#8804;MFC&#8804;0,31 mg/mL). Concerning Cryptococcus spp., the 25 strains tested, MFC values for pravastatin were found against three strains (MFC=50 mg/mL), while those for simvastatin were determined against 21 strains (0.12&#8804;MFC&#8804;1 mg/mL) and those for atorvastatin were determined against one single strain (MFC=1 mg/mL). This in vitro inhibitory activity of statins against Candida spp. and Cryptococcus spp. creates an important perspective for the use of these drugs in vivo in order to control fungal infections.